Reformulating cyclosporine A (CsA): More than just a life cycle management strategy

Survase, 2011, Cyclosporin A — a review on fermentative production, downstream processing and pharmacological applications, Biotechnol. Adv., 29, 418, 10.1016/j.biotechadv.2011.03.004 Pawarode, 2010, Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia, Leuk. Lymphoma, 51, 338, 10.3109/10428190903470851 Lulic, 2011, A review of laboratory and clinical data supporting the safety and efficacy of cyclosporin A in traumatic brain injury, Neurosurgery, 68, 1172, 10.1227/NEU.0b013e31820c6cdc Osman, 2011, Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application, Neuropeptides, 45, 359, 10.1016/j.npep.2011.04.002 Hamdy, 2011, The immunosuppressive activity of polymeric micellar formulation of cyclosporine A: in vitro and in vivo studies, AAPS J., 13, 159, 10.1208/s12248-011-9259-8 Lei, 2012, Solid self-nanoemulsifying cyclosporine A pellets prepared by fluid-bed coating: stability and bioavailability study, J. Biomed. Nanotechnol., 8, 515, 10.1166/jbn.2012.1400 Zhang, 2013, Preparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles, Int. J. Nanomedicine, 8, 601 Dai, 2015, Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A, Int. J. Pharm., 478, 718, 10.1016/j.ijpharm.2014.11.030 Beauchesne, 2007, Cyclosporine A: a review of current oral and intravenous delivery systems, Drug Dev. Ind. Pharm., 33, 211, 10.1080/03639040601155665 El Tayar, 1993, Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations, J. Med. Chem., 36, 3757, 10.1021/jm00076a002 Wenger, 1986, Cyclosporine: chemistry, structure–activity relationships and mode of action, 157 Matsuda, 2000, Mechanisms of action of cyclosporine, Immunopharmacology, 47, 119, 10.1016/S0162-3109(00)00192-2 Archer, 2014, Oral cyclosporine treatment in dogs: a review of the literature, J. Vet. Intern. Med., 28, 1, 10.1111/jvim.12265 Hausenloy, 2012, Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent, Br. J. Pharmacol., 165, 1235, 10.1111/j.1476-5381.2011.01700.x Lindholm, 1991, Factors influencing the pharmacokinetics of cyclosporine in man, Ther. Drug Monit., 13, 465, 10.1097/00007691-199111000-00001 Freeman, 1991, Pharmacology and pharmacokinetics of cyclosporine, Clin. Biochem., 24, 9, 10.1016/0009-9120(91)90084-R Christians, 1993, Cyclosporin metabolism in transplant patients, Pharmacol. Ther., 57, 291, 10.1016/0163-7258(93)90059-M European Multicentre Trial Group, 1983, Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial, Lancet, 322, 986, 10.1016/S0140-6736(83)90978-9 Azzi, 2013, Calcineurin inhibitors: 40years later, can't live without, J. Immunol., 191, 5785, 10.4049/jimmunol.1390055 Weber, 2006, Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (neoral), Inflamm. Bowel Dis., 12, 1131, 10.1097/01.mib.0000235096.78736.8e Kornbluth, 2011, Cyclosporine versus infliximab for the treatment of severe ulcerative colitis, Gastroenterol. Hepatol., 7, 677 Zhao, 2013, Treatment of T-cell large granular lymphocyte leukemia with cyclosporine A: experience in a Chinese single institution, Leuk. Res., 37, 547, 10.1016/j.leukres.2013.01.017 Italia, 2006, Disease, destination, dose and delivery aspects of ciclosporin: the state of the art, Drug Discov. Today, 11, 846, 10.1016/j.drudis.2006.07.015 Wallemacq, 2004, Therapeutic monitoring of immunosuppressant drugs. Where are we?, Clin. Chem. Lab. Med., 42, 1204, 10.1515/CCLM.2004.242 Feutren, 1992, The optimal use of cyclosporin A in autoimmune diseases, J. Autoimmun., 5, 183, 10.1016/0896-8411(92)90033-M Issa, 2013, Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence, Am. J. Nephrol., 37, 602, 10.1159/000351648 Lee, 2007, 5, 126 Naesens, 2009, Calcineurin inhibitor nephrotoxicity, Clin. J. Am. Soc. Nephrol., 4, 481, 10.2215/CJN.04800908 Bennet, 1986, Action and toxicity of cyclosporine, Annu. Rev. Med., 37, 215, 10.1146/annurev.me.37.020186.001243 Lindholm, 1988, Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing, Eur. J. Clin. Pharmacol., 34, 461, 10.1007/BF01046702 Chiu, 2003, Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in caco-2 cells, Pharm. Res., 20, 749, 10.1023/A:1023481418576 Andrysek, 2003, Impact of physical properties of formulations on bioavailability of active substance: current and novel drugs with cyclosporine, Mol. Immunol., 39, 1061, 10.1016/S0161-5890(03)00077-4 Schiff, 2007, Therapeutic monitoring of calcineurin inhibitors for the nephrologist, Clin. J. Am. Soc. Nephrol., 2, 374, 10.2215/CJN.03791106 Taber, 2005, Does bioequivalence between modified cyclosporine formulations translate into equal outcomes?, Transplantation, 80, 1633, 10.1097/01.tp.0000188688.15639.03 B. Steve Campbell, E. Elmér, M. Bronnegard, TBI Pharmaceuticals—The long odyssey of cyclosporine is almost over, http://www.internationalbrain.org/tbi-pharmaceuticals-the-long-odyssey-of-cyclosporine/ (last access: 10/22/2015). Ehinger, 2013, Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in cremophor® EL, Clin. Drug Invest., 33, 25, 10.1007/s40261-012-0029-x Amidon, 1995, A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413, 10.1023/A:1016212804288 Barany, 2001, Effect of 6weeks of vitamin E administration on renal haemodynamic alterations following a single dose of neoral in healthy volunteers, Nephrol. Dial. Transplant., 16, 580, 10.1093/ndt/16.3.580 Lallemand, 2003, Cyclosporine A delivery to the eye: A pharmaceutical challenge, Eur. J. Pharm. Biopharm., 56, 307, 10.1016/S0939-6411(03)00138-3 Shen, 2010, Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution, Int. J. Pharm., 402, 248, 10.1016/j.ijpharm.2010.10.008 Basaran, 2010, Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery, J. Microencapsul., 27, 37, 10.3109/02652040902846883 Sandri, 2010, Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems, J. Microencapsul., 27, 735, 10.3109/02652048.2010.517854 Battaglia, 2012, Solid lipid nanoparticles prepared by coacervation method as vehicles for ocular cyclosporine, J. Drug Delivery Sci. Technol., 22, 125, 10.1016/S1773-2247(12)50016-X Wolska, 2013, Technology of stable, prolonged-release eye-drops containing cyclosporine A, distributed between lipid matrix and surface of the solid lipid microspheres (SLM), Int. J. Pharm., 441, 449, 10.1016/j.ijpharm.2012.11.009 Guada, 2015, Lipid nanoparticles for cyclosporine A administration: development, characterization and in vitro evaluation of their immunosuppression activity, Int. J. Nanomedicine, 10, 6541 Guada, 2016, Lipid nanoparticles enhance the absorption of Cyclosporine A through the gastrointestinal barrier: in vitro and in vivo studies, Int. J. Pharm., 500, 154, 10.1016/j.ijpharm.2016.01.037 Jain, 2015, Cyclosporine A loaded self-nanoemulsifying drug delivery system (SNEDDS): implication of functional Excipient Based Co-encapsulation strategy on oral bioavailability and nephrotoxicity, RSC Adv., 49633, 10.1039/C5RA04762E Zhang, 2013, Controlled release of cyclosporine A self-nanoemulsifying systems from osmotic pump tablets: near zero-order release and pharmacokinetics in dogs, Int. J. Pharm., 452, 233, 10.1016/j.ijpharm.2013.05.014 Avramoff, 2012, Cyclosporin pro-dispersion liposphere formulation, J. Control. Release, 160, 401, 10.1016/j.jconrel.2011.12.016 Avramoff, 2007, Comparative in vivo bioequivalence and in vitro dissolution of two cyclosporin A soft gelatin capsule formulations, Int. J. Clin. Pharmacol. Ther., 45, 126, 10.5414/CPP45126 Guan, 2011, Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt, Int. J. Nanomedicine, 6, 965 Karavana, 2012, A new approach to the treatment of recurrent aphthous stomatitis with bioadhesive gels containing cyclosporine A solid lipid nanoparticles: in vivo/in vitro examinations, Int. J. Nanomedicine, 7, 5693, 10.2147/IJN.S36883 Yin, 2014, Cyclosporine A-nanoparticles enhance the therapeutic benefit of adipose tissue-derived stem cell transplantation in a swine myocardial infarction model, Int. J. Nanomedicine, 9, 17 Gan, 2013, Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers, Drug Discov. Today, 18, 290, 10.1016/j.drudis.2012.10.005 Souto, 2010, Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs, Curr. Eye Res., 35, 537, 10.3109/02713681003760168 Müller, 2000, Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art, Eur. J. Pharm. Biopharm., 50, 161, 10.1016/S0939-6411(00)00087-4 Alonso-Sande, 2013, Development of PLGA-mannosamine nanoparticles as oral protein carriers, Biomacromolecules, 14, 4046, 10.1021/bm401141u De Campos, 2001, Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A, Int. J. Pharm., 224, 159, 10.1016/S0378-5173(01)00760-8 Beloqui, 2016, Nanostructured lipid carriers: promising drug delivery systems for future clinics, Nanomedicine, 12, 143, 10.1016/j.nano.2015.09.004 Memvanga, 2013, An oral malaria therapy: curcumin-loaded lipid-based drug delivery systems combined with β-arteether, J. Control. Release, 172, 904, 10.1016/j.jconrel.2013.09.001 Sercombe, 2015, Advances and challenges of liposome assisted drug delivery, Front. Pharmacol., 6, 286, 10.3389/fphar.2015.00286 Wu, 2015, Oral delivery of liposomes, Ther. Deliv., 6, 1239, 10.4155/tde.15.69 Hu, 2013, Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media, Int. J. Pharm., 441, 693, 10.1016/j.ijpharm.2012.10.025 Rahman, 2010, Understanding the quality of protein loaded PLGA nanoparticles variability by plackett–Burman design, Int. J. Pharm., 389, 186, 10.1016/j.ijpharm.2009.12.040 Hermans, 2010, The effect of HPβCD on cyclosporine A in-vitro release from PLGA nanoparticles, J. Control. Release, 148, e40, 10.1016/j.jconrel.2010.07.048 Takebe, 2011, Preparation of polymeric nanoparticles of cyclosporin A using infrared pulsed laser, Int. J. Pharm., 414, 244, 10.1016/j.ijpharm.2011.05.012 Bader, 2011, Polysialic acid-based micelles for encapsulation of hydrophobic drugs, Biomacromolecules, 12, 314, 10.1021/bm1008603 Jelonek, 2011, Controlled poly (l-lactide-co-trimethylene carbonate) delivery system of cyclosporine A and rapamycine–the effect of copolymer chain microstructure on drug release rate, Int. J. Pharm., 414, 203, 10.1016/j.ijpharm.2011.05.035 Tang, 2012, Immunosuppressive activity of size-controlled PEG-PLGA nanoparticles containing encapsulated cyclosporine A, J. Transplant., 2012, 896141, 10.1155/2012/896141 Hermans, 2012, Full factorial design, physicochemical characterisation and biological assessment of cyclosporine A loaded cationic nanoparticles, Eur. J. Pharm. Biopharm., 82, 27, 10.1016/j.ejpb.2012.05.003 Wilson, 2014, Synthesis and evaluation of cyclosporine A-loaded polysialic acid–polycaprolactone micelles for rheumatoid arthritis, Eur. J. Pharm. Sci., 51, 146, 10.1016/j.ejps.2013.09.013 Rahman, 2010, Formulation and evaluation of a protein-loaded solid dispersions by non-destructive methods, AAPS J., 12, 158, 10.1208/s12248-009-9171-7 Keohane, 2014, Silicon microfluidic flow focusing devices for the production of size-controlled PLGA based drug loaded microparticles, Int. J. Pharm., 467, 60, 10.1016/j.ijpharm.2014.03.051 Mondon, 2011, Novel cyclosporin A formulations using MPEG–hexyl-substituted polylactide micelles: A suitability study, Eur. J. Pharm. Biopharm., 77, 56, 10.1016/j.ejpb.2010.09.012 Cao, 2015, Synergistic effects of zinc oxide nanoparticles and fatty acids on toxicity to caco-2 cells, Int. J. Toxicol., 34, 67, 10.1177/1091581814560032 Ankola, 2010, Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A, J. R. Soc. Interface, 7, S475 Ankola, 2011, Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match neoral cmax sparing the kidney from damage, J. Biomed. Nanotechnol., 7, 300, 10.1166/jbn.2011.1278 Venkatpurwar, 2015, Drug-not carrier-dependent haematological and biochemical changes in a repeated dose study of cyclosporine encapsulated polyester nano-and micro-particles: size does not matter, Toxicology, 330, 9, 10.1016/j.tox.2015.01.017 Siew, 2011, Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles, Mol. Pharm., 9, 14, 10.1021/mp200469a Lai, 2010, Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles, Int. J. Nanomedicine, 5, 13 Fukata, 2011, The effective therapy of cyclosporine A with drug delivery system in experimental colitis, J. Drug Target., 19, 458, 10.3109/1061186X.2010.511224 Yu, 2013, Supersaturated polymeric micelles for oral cyclosporine A delivery, Eur. J. Pharm. Biopharm., 85, 1325, 10.1016/j.ejpb.2013.08.003 Azzi, 2010, Polylactide-cyclosporin A nanoparticles for targeted immunosuppression, FASEB J., 24, 3927, 10.1096/fj.10-154690 Jyothi, 2015, Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication, Int. J. Nanomedicine, 10, 903 Aksungur, 2011, Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies, J. Control. Release, 151, 286, 10.1016/j.jconrel.2011.01.010 Basaran, 2013, Chitosan nanoparticles for ocular delivery of cyclosporine A, J. Microencapsul., 31, 49, 10.3109/02652048.2013.805839 Di Tommaso, 2012, Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies, Eur. J. Pharm. Biopharm., 81, 257, 10.1016/j.ejpb.2012.02.014 Wang, 2012, pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs, Eur. J. Pharm. Biopharm., 82, 219, 10.1016/j.ejpb.2012.07.014 Müller, 2006, Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals, Int. J. Pharm., 317, 82, 10.1016/j.ijpharm.2006.02.045 Beloqui, 2013, Biodistribution of nanostructured lipid carriers (NLCs) after intravenous administration to rats: influence of technological factors, Eur. J. Pharm. Biopharm., 84, 309, 10.1016/j.ejpb.2013.01.029 Reimondez-Troitiño, 2015, Nanotherapies for the treatment of ocular diseases, Eur. J. Pharm. Biopharm., 95, 279, 10.1016/j.ejpb.2015.02.019 Wu, 2013, Enhanced and sustained topical ocular delivery of cyclosporine A in thermosensitive hyaluronic acid-based in situ forming microgels, Int. J. Nanomedicine, 8, 3587 Eperon, 2013, A new drug delivery system inhibits uveitis in an animal model after cataract surgery, Int. J. Pharm., 443, 254, 10.1016/j.ijpharm.2012.12.033 Gupta, 2011, Ophthalmic delivery of cyclosporine A by punctal plugs, J. Control. Release, 150, 70, 10.1016/j.jconrel.2010.11.009 Rodriguez-Aller, 2013, In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application, J. Control. Release, 170, 153, 10.1016/j.jconrel.2013.04.019 Kim, 2009, Topical administration of cyclosporin A in a solid lipid nanoparticle formulation, Pharmazie, 64, 510 Frušić-Zlotkin, 2012, Penetration and biological effects of topically applied cyclosporin A nanoparticles in a human skin organ culture inflammatory model, Exp. Dermatol., 21, 938, 10.1111/exd.12051 Watts, 2009, Recent developments in drug delivery to prolong allograft survival in lung transplant patients, Drug Dev. Ind. Pharm., 35, 259, 10.1080/03639040802282904 Wu, 2013, Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery, Int. J. Nanomedicine, 8, 1269 Baiza-Duran, 2010, A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome, Br. J. Ophthalmol., 94, 1312, 10.1136/bjo.2008.150011 Shi, 2013, A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study, Ophthalmology, 120, 695, 10.1016/j.ophtha.2012.09.035